vs
Orthofix Medical Inc.（OFIX）与PROASSURANCE CORP（PRA）财务数据对比。点击上方公司名可切换其他公司
PROASSURANCE CORP的季度营收约是Orthofix Medical Inc.的1.2倍（$269.6M vs $219.9M），PROASSURANCE CORP净利率更高（12.4% vs -1.0%，领先13.4%），Orthofix Medical Inc.同比增速更快（2.0% vs -7.1%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -2.7%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
保信集团（ProAssurance）总部位于美国阿拉巴马州伯明翰，是一家财产意外保险公司，主打面向医生的职业责任保险业务。公司前身为1976年成立的Mutual Assurance，1997年更名为Medical Assurance，2001年与Professionals Group合并后改为现名，目前是全美第四大医疗职业责任险承保机构，总资产超60亿美元。
OFIX vs PRA — 直观对比
营收规模更大
PRA
是对方的1.2倍
$219.9M
营收增速更快
OFIX
高出9.0%
-7.1%
净利率更高
PRA
高出13.4%
-1.0%
两年增速更快
OFIX
近两年复合增速
-2.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $269.6M |
| 净利润 | $-2.2M | $33.4M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | 17.3% |
| 净利率 | -1.0% | 12.4% |
| 营收同比 | 2.0% | -7.1% |
| 净利润同比 | 92.4% | 106.4% |
| 每股收益（稀释后） | $-0.05 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXPRA
| Q4 25 | $219.9M | $269.6M | ||
| Q3 25 | $205.6M | $279.6M | ||
| Q2 25 | $203.1M | $276.8M | ||
| Q1 25 | $193.6M | $272.1M | ||
| Q4 24 | $215.7M | $290.1M | ||
| Q3 24 | $196.6M | $285.3M | ||
| Q2 24 | $198.6M | $290.4M | ||
| Q1 24 | $188.6M | $284.7M |
净利润OFIXPRA
| Q4 25 | $-2.2M | $33.4M | ||
| Q3 25 | $-22.8M | $1.4M | ||
| Q2 25 | $-14.1M | $21.9M | ||
| Q1 25 | $-53.1M | $-5.8M | ||
| Q4 24 | $-29.1M | $16.2M | ||
| Q3 24 | $-27.4M | $16.4M | ||
| Q2 24 | $-33.4M | $15.5M | ||
| Q1 24 | $-36.0M | $4.6M |
毛利率OFIXPRA
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — | ||
| Q1 24 | 67.5% | — |
营业利润率OFIXPRA
| Q4 25 | 0.2% | 17.3% | ||
| Q3 25 | -8.3% | 1.6% | ||
| Q2 25 | -7.9% | 9.9% | ||
| Q1 25 | -25.2% | -2.3% | ||
| Q4 24 | -5.3% | 6.5% | ||
| Q3 24 | -9.6% | 7.4% | ||
| Q2 24 | -12.5% | 6.2% | ||
| Q1 24 | -15.6% | 1.9% |
净利率OFIXPRA
| Q4 25 | -1.0% | 12.4% | ||
| Q3 25 | -11.1% | 0.5% | ||
| Q2 25 | -6.9% | 7.9% | ||
| Q1 25 | -27.4% | -2.1% | ||
| Q4 24 | -13.5% | 5.6% | ||
| Q3 24 | -13.9% | 5.8% | ||
| Q2 24 | -16.8% | 5.3% | ||
| Q1 24 | -19.1% | 1.6% |
每股收益（稀释后）OFIXPRA
| Q4 25 | $-0.05 | $0.65 | ||
| Q3 25 | $-0.57 | $0.03 | ||
| Q2 25 | $-0.36 | $0.42 | ||
| Q1 25 | $-1.35 | $-0.11 | ||
| Q4 24 | $-0.76 | $0.32 | ||
| Q3 24 | $-0.71 | $0.32 | ||
| Q2 24 | $-0.88 | $0.30 | ||
| Q1 24 | $-0.95 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $36.5M |
| 总债务越低越好 | — | $420.4M |
| 股东权益账面价值 | $450.0M | $1.3B |
| 总资产 | $850.6M | $5.4B |
| 负债/权益比越低杠杆越低 | — | 0.31× |
8季度趋势，按日历期对齐
现金及短期投资OFIXPRA
| Q4 25 | $82.0M | $36.5M | ||
| Q3 25 | $62.9M | $54.5M | ||
| Q2 25 | $65.6M | $41.6M | ||
| Q1 25 | $58.0M | $43.5M | ||
| Q4 24 | $83.2M | $54.9M | ||
| Q3 24 | $30.1M | $45.3M | ||
| Q2 24 | $26.4M | $36.9M | ||
| Q1 24 | $27.0M | $65.4M |
总债务OFIXPRA
| Q4 25 | — | $420.4M | ||
| Q3 25 | $157.2M | $421.5M | ||
| Q2 25 | $157.0M | $422.6M | ||
| Q1 25 | $156.9M | $423.7M | ||
| Q4 24 | $157.0M | $424.9M | ||
| Q3 24 | $118.5M | $425.9M | ||
| Q2 24 | $118.0M | $426.9M | ||
| Q1 24 | $118.2M | $427.8M |
股东权益OFIXPRA
| Q4 25 | $450.0M | $1.3B | ||
| Q3 25 | $442.5M | $1.3B | ||
| Q2 25 | $458.3M | $1.3B | ||
| Q1 25 | $458.3M | $1.2B | ||
| Q4 24 | $503.1M | $1.2B | ||
| Q3 24 | $525.9M | $1.2B | ||
| Q2 24 | $546.0M | $1.1B | ||
| Q1 24 | $570.3M | $1.1B |
总资产OFIXPRA
| Q4 25 | $850.6M | $5.4B | ||
| Q3 25 | $832.6M | $5.6B | ||
| Q2 25 | $837.2M | $5.5B | ||
| Q1 25 | $823.1M | $5.5B | ||
| Q4 24 | $893.3M | $5.6B | ||
| Q3 24 | $867.9M | $5.7B | ||
| Q2 24 | $882.0M | $5.6B | ||
| Q1 24 | $906.0M | $5.7B |
负债/权益比OFIXPRA
| Q4 25 | — | 0.31× | ||
| Q3 25 | 0.36× | 0.32× | ||
| Q2 25 | 0.34× | 0.33× | ||
| Q1 25 | 0.34× | 0.34× | ||
| Q4 24 | 0.31× | 0.35× | ||
| Q3 24 | 0.23× | 0.35× | ||
| Q2 24 | 0.22× | 0.38× | ||
| Q1 24 | 0.21× | 0.38× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $-25.6M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | -0.77× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXPRA
| Q4 25 | $27.7M | $-25.6M | ||
| Q3 25 | $12.4M | $27.2M | ||
| Q2 25 | $11.6M | $-28.1M | ||
| Q1 25 | $-18.4M | $-11.6M | ||
| Q4 24 | $23.7M | $-10.7M | ||
| Q3 24 | $11.7M | $14.0M | ||
| Q2 24 | $9.0M | $-12.8M | ||
| Q1 24 | $-18.6M | $-11.6M |
自由现金流OFIXPRA
| Q4 25 | $16.8M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | $-25.1M | — | ||
| Q4 24 | $15.2M | — | ||
| Q3 24 | $6.3M | — | ||
| Q2 24 | $-360.0K | — | ||
| Q1 24 | $-29.1M | — |
自由现金流率OFIXPRA
| Q4 25 | 7.6% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | -13.0% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | -0.2% | — | ||
| Q1 24 | -15.4% | — |
资本支出强度OFIXPRA
| Q4 25 | 4.9% | — | ||
| Q3 25 | 4.8% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 5.6% | — |
现金转化率OFIXPRA
| Q4 25 | — | -0.77× | ||
| Q3 25 | — | 18.81× | ||
| Q2 25 | — | -1.28× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.66× | ||
| Q3 24 | — | 0.85× | ||
| Q2 24 | — | -0.83× | ||
| Q1 24 | — | -2.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
PRA
| Workers Compensation Insurance Segment | $164.4M | 61% |
| Other | $59.6M | 22% |
| Segregated Portfolio Cell Reinsurance | $45.7M | 17% |
